Chronic kidney disease is a progressive disease with no cure and high morbidity and
mortality that occurs commonly in the general adult population, especially in people with …

Chronic kidney disease (CKD) is a complex disease which affects approximately 13% of the
world's population. Over time, CKD can cause renal dysfunction and progression to end …

Background The effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on kidney
failure, particularly the need for dialysis or transplantation or death due to kidney disease, is …

The original KDIGO Clinical Practice Guideline for the Management of Blood Pressure in
Chronic Kidney Disease in the chronic kidney disease (CKD) population not receiving …

Hyperkalemia is an electrolyte abnormality with potentially life-threatening consequences.
Despite various guidelines, no universally accepted consensus exists on best practices for …

Since the first description of the association between chronic kidney disease and heart
disease, many epidemiological studies have confirmed and extended this finding. As …

Background The effects of the sodium-glucose co-transporter 2 inhibitor empagliflozin on
renal and cardiovascular disease have not been tested in a dedicated population of people …

Background It is unknown whether stop** renin-angiotensin system (RAS) inhibitor
therapy in patients with advanced CKD affects outcomes. Methods We studied patients …

Diabetes is a common cause of chronic kidney disease (CKD), but in aggregate, non-
diabetic diseases account for a higher proportion of cases of CKD than diabetes in many …

Significant disparities in CKD rates and outcomes exist between black and white Americans.
Health disparities are defined as health differences that adversely affect disadvantaged …